IMPORTANCE Transportation barriers contribute to missed primary care appointments for patients with Medicaid. Rideshare services have been proposed as alternatives to nonemergency medical transportation programs because of convenience and lower costs.
L ow-income patients frequently face transportation barriers when accessing primary care. In several large surveys, 24% to 51% respondents reported missing or rescheduling an outpatient appointment because of unreliable transportation.
1,2 When faced with transportation barriers, patients shift their care toward more costly, acute care settings for low-acuity needs because of preference and convenience.
2-8
For health care professionals, missed appointments have a negative effect on clinical productivity. 2-4,9 Unused clinical space and staff time equate to lost revenue. Nonemergency medical transportation (NEMT) is a Medicaid benefit provided to decrease transportation barriers. However, despite the availability of NEMT services, transportation barriers persist for many Medicaid patients. [10] [11] [12] The design of NEMT services may be a contributor: the services require advanced scheduling (often days in advance), travel times can be long due to indirect travel routes related to picking up and dropping off other passengers, and pick-up wait times can be long. 10 Rideshare services provided by companies such as Uber and Lyft have been proposed as NEMT alternatives because they can be scheduled as needed, use direct routes, are readily available in most urban areas, and cost less.
13-15
We developed a model for providing rideshare-based transportation using a web-based rideshare dispatch platform provided by Lyft Inc. We tested the association between this rideshare-based transportation service model and the rate of missed appointments for Medicaid patients at 2 primary care practices in Philadelphia, Pennsylvania.
Methods

Overview
We conducted a prospective clinical trial between October 24, 2016, and April 20, 2017, using a fixed allocation scheme to test the association between offering a rideshare-based transportation service (referred to as Lyft ride) and missed primary care appointments for Medicaid patients at 2 primary care practices. The trial protocol is available in Supplement 1. The practices were academic general internal medicine clinics that are part of Penn Medicine (University of Pennsylvania) and located in Philadelphia. The primary hypothesis was that the rate of missed appointments among those allocated to the intervention arm would be lower than the rate of missed appointments among comparable controls. We allocated patients into the intervention or control arm based on day of the week of a prescheduled phone appointment reminder (2 business days before their appointment). Those called on an evennumbered weekday were allocated to the intervention arm (phone appointment reminder plus Lyft ride offer) and those called on an odd-numbered weekday were allocated to the control arm (phone appointment reminder only). We used this allocation scheme rather than individual-level randomization due to logistical limitations of our research staffing. These study-specific reminder calls from research staff were in addition to automated appointment reminder calls that were part of the usual reminder system for the study practices.
This study was approved by the institutional review board at the University of Pennsylvania. Informed oral consent was obtained to notify patients in the intervention arm of their rights and risks when using Lyft vehicles for transportation. There was no financial compensation.
Study Population and Phone Call Procedures
Patients eligible for study inclusion were (1) adults (age ≥18 years), (2) insured by Medicaid, (3) established primary care patients (ie, scheduled for a return visit instead of a new patient visit) at 1 of the 2 study practices, (4) resided within the highpoverty neighborhood of West Philadelphia, (5) scheduled to see a physician or nurse practitioner (eg, not a blood pressure check by a registered nurse or follow-up immunization injection), and (6) not already allocated to a study arm or offered the service previously during our pilot period described below. Eligibility was screened prior to calling a patient.
Patients allocated to the intervention or control arm received a phone appointment reminder from a research assistant 2 business days before the scheduled appointment. No voicemails were left for patients in either study arm. If patients returned a missed phone call in either arm, we answered calls during the hours of 9 AM to 6 PM. In these instances, patients received the study procedures based on their original allocation.
Also, as part of usual care, each patient received an automated phone call (ie, "robo call") 2 days before their appointment. These automatic calls occurred throughout the study in both arms. Therefore, patients in both arms received 2 types of phone call reminders for their upcoming appointments: 1 from an automated practice-based system and 1 from our research team, with a maximum of 3 attempts by our research assistants to make verbal contact.
Control Arm
Patients allocated to the control arm received the robo calls and phone call reminders from our study staff. During phone call reminders, the patients were blinded to the intervention.
during an earlier pilot period. A description of the pilot test and quality assurance measures are provided in the eAppendix in Supplement 2. For intervention arm patients who answered the phone call, we assessed for logistical barriers to using Lyft services (lacking a text message-enabled phone, requiring a wheelchair-accessible vehicle, or not speaking English). Patients with 1 or more of these barriers were not offered a Lyft ride but were not excluded from the primary intent-to-treat analysis because those in the control arm were not screened for these barriers.
After confirming study eligibility, the research assistant asked patients whether they would be willing to spend additional time to learn about the study and using Lyft for transportation to and from their appointment. For consenting patients, a Lyft ride to their appointment was prescheduled using a web-based application designed by Lyft (the Dispatch tool). The Dispatch tool mirrors the mobile phone app available to Lyft users, permitting app-based ride requests and the ability to visualize rides while in transit to a specific destination for pickup and drop offs. Using the Dispatch tool, the requests were initiated and driver routes visualized by a research assistant, but not by the patient.
The Dispatch tool circumvents the need for patients to have a smartphone or app. When a Lyft ride was triggered using the Dispatch tool, the patient received a sequential series of text messages stating that (1) the ride had been scheduled by our team, (2) a driver was assigned to pick the patient up (received approximately 10 minutes before the driver's arrival), and (3) the driver had arrived at the preassigned pickup destination. Like the consumer experience of using Lyft through the smartphone app, patients received a text message containing the name, telephone number, vehicle make and model, and vehicle license plate number when a driver was assigned to pick them up. Unlike typical use, pick-up and drop-off locations were limited to the patient's home and the internal medicine practices.
For the return trip home, patients were provided a telephone number to call after their appointment was completed. A research assistant received their request and initiated a ride home using the Dispatch tool. Patients received the same 3 text message series for the return ride. Patients were provided the option to receive round-trip (to and from their appointment) or 1-way (to or from their appointment) transportation service.
Incentives and Payment
No incentives other than free Lyft rides made available to patients in the intervention arm were provided for participating in the study. Neither patients nor the research team tipped drivers. The ride service was offered to patients free of charge, mirroring the out-of-pocket costs these practices' patients experience using the NEMT program from Medicaid.
Measures and Data Collection
The prespecified primary outcome (missed appointment rate) was calculated for the intervention and control arms. Missed appointment rates were calculated as the number of no-shows and same-day cancellations divided by the total number of patients in the study arm based on data within the electronic medical record. Secondary prespecified outcomes were rates of emergency department visits within 7 days and 30 days after the primary care appointment. Emergency department utilization data were limited to health services provided by Penn Medicine facilities. As 1 measure of program costs, we collected financial data from the Dispatch tool.
Baseline measures for all patients were extracted from the medical record, which included demographic information (sex, age, race, and ethnicity), Medicaid insurance company, Charlson comorbidity index score, the type of health care professional (attending physician, resident physician, or advanced practice nurse) they were scheduled to see, and the type of visit (eg, return visit vs posthospitalization follow-up). The driving distance between their residential address listed in the medical record and the clinical practices was calculated using ArcGIS, version 10.3 (Esri).
Statistical Analysis
Comparisons of baseline demographics and comorbidity data between intervention and control arm patients were conducted using χ 2 or Wilcoxon rank-sum tests. Unadjusted comparisons for our primary and secondary outcomes were conducted using χ 2 analysis. Logistic regression models were used to adjust for specific covariates with imbalances between treatment arms. The study, with at least 390 patients per arm, was designed to have 80% power to detect a 10% absolute difference in missed appointment rates between arms at a 2-sided α level of .05. This calculation was based on an estimated missed appointment rate of 49% based on the rate for the same internal medicine practices in the prior calendar year using the same eligibility criteria. Given that, to our knowledge, there were no previous trials of rideshare services, we judged that a 10% absolute reduction would be a meaningful difference for health system and insurance leadership.
Primary analyses used an intention-to-treat approach. The analytic sample was defined as all patients receiving a phone call initiated by 1 of our research assistants in either arm of the study. Patients were not excluded from the primary analysis if they did not answer the phone and, for those in the intervention arm, declined the ride or were screened from being offered a Lyft ride. The transportation cost per person in the intervention arm who consented to receive a Lyft ride was calculated, including the costs of rides taken and standard charges ($5-$10) from Lyft for missing a scheduled ride. We did not account for the cost of research staff time, which consisted of medical students participating in a research experience, nor did we capture the facility space costs (ie, the rooms and computers they called from) that are shared across multiple research projects.
Exploratory analyses included analyzing the as-treated group to investigate the potential result of not answering our phone call reminder. Additional exploratory analyses were performed assessing an association between the intervention and types of missed appointments (eg, no-shows and same-day cancellations) and by subgroups of demographics. Driving distance from the clinic and Charlson comorbidity index scores were stratified above and below the median.
Our study used outcome measures that were available in the electronic medical record. Therefore, we had no missing data for our outcomes. All hypothesis testing was conducted using a 2-sided, type I error rate of 0.05. All analyses were carried out using Stata, version 14.0 (StataCorp LLP).
Results
Patient Characteristics
The study sample included 786 patients, with 394 patients in the intervention arm and 392 in the control arm (Figure) . Patients were predominantly black, non-Hispanic women; mean (SD) age was 46.0 (12.5) years (Table 1) . Study arms were balanced with respect to sex, age, race/ethnicity, driving distance, Charlson comorbidity index score, Medicaid insurer, and type of outpatient appointment. There were significant differences in the type of health care professional that patients were scheduled to see, with a higher proportion of attending physicians (28.8% vs 23.6%) and nurse practitioners or physician assistants (15.8% vs 10.4%) for the control arm compared with the intervention arm (P < .01). For the control arm, 270 (68.9%) individuals answered the phone calls compared with 288 (73.1%) in the intervention arm (P = .19). Within the intervention arm, 162 (56.3%) people were not interested in rideshare. Among the 288 patients who answered the phone, 104 (36.1%) were interested, 11 (3.8%) were not offered the Lyft ride because they needed a wheelchair-accessible ride or did not have a text-capable phone, 93 (32.3%) consented and had a ride to clinic scheduled, and 85 (26.0%) used the service ( Table 2) .
Main Outcomes
For our prespecified primary outcome of interest, the missed appointment rate in the intervention arm was 36.5% vs 36.7% (P = .96) in the control arm (Table 3) . Adjusting for the imbalance in provider types did not affect our results (eTable 1 in Supplement 2). For our prespecified secondary outcomes of interest, there were no significant differences in 7-day or 30-day rates of emergency department visits in the unadjusted or adjusted analyses controlling for clinician types. The mean (SD) cost per patient who consented was $14.00 ($6.88); range, $0 to $40.17. ED indicates emergency department.
Research Original Investigation
Rideshare-Based Transportation Services and Missed Primary Care Appointments
Exploratory As-Treated and Subgroup Analyses
Among individuals who answered the phone, the missed appointment rate was 30.6% (88 of 288) in the intervention arm and 34.8% (94 of 270) in the control arm (P = .28).
Evaluations of emergency department utilization in the unadjusted analyses or adjusted models remained statistically nonsignificant. Analyses assessing the association between the intervention and same-day cancellations and no-shows separately did not yield any significant findings in the intention-to-treat cohort or the as-treated group. There were no statistically significant intervention results in any patient subgroups (eTable 2 in Supplement 2).
Discussion
This study examined rideshare-based medical transportation for Medicaid patients at 2 urban, academic, general internal medicine practices. Few patients used ridesharebased medical transportation services for travel to and from their primary care appointment. We observed no significant difference in missed appointment rates for patients offered a Lyft ride compared with those in the control arm. At the time we designed the study, there were several reasons to hypothesize that the intervention might succeed. Transportation is a notable barrier for Medicaid patients, despite having access to NEMT-based services.
2,3 Medicaid patients have significantly high rates of missed appointments compared with other populations and our population mirrored missed appointment rates reported in other studies. 2,10 Rideshare-based transportation was being explored as a viable alternative to NEMT 13,15 ; however, we found no significant improvement in missed appointments.
Limitations
One possibility for the lack of improvement is that transportation-based strategies to reduce missed appointments do not work in our setting. Transportation may not have as much of an impact in our geographic region because the furthest point in West Philadelphia is less than 5 miles from the clinics and the public transportation network of buses and trolleys is extensive in our area. However, prior studies conducted in urban environments indicate that, even with short geographic distance and public transportation access, transportation remains a barrier. Second, transportation may be 1 of many factors influencing reasons why patients choose to miss or attend their primary care appointment. Other social risk factors, such as the stability of their home environment, may limit a patient's ability to attend appointments.
Third, our recruitment strategy may have affected the number of patients who used the service. Phone calls may not be the best way to contact patients to offer a new service. Inperson communication, text messages, or emails may be more effective in recruiting patients. However, our study recruitment strategy balanced several competing issues, including limitations in our research staffing model and a desire by the health system to limit call-backs related to offering the service, which could, should it be fully implemented, impede practice workflow.
Fourth, we did not measure comfort with using text message communication. If patients were uncomfortable with text communication, which was required to dispatch ridesharing services, it could have resulted in low overall uptake of the service. However, this is unlikely to lead to differences between study arms based on our allocation scheme. Future studies should measure comfort levels with cellphone or smartphone technology as this may be an important mediator between the effect of rideshare-based interventions and outcomes, such as missed appointments.
Fifth, there was a secular change within the health system, or at least within these 2 clinics, resulting in fewer overall missed appointments. The change from 49% in the calendar year leading up to the start of our study to 36% is substantial. Clinic leadership reported that there were no changes in appointment reminder practices. This reduction suggests that something more powerful than our intervention may have occurred. Similarly, the missed appointment rate among control patients who answered our phone call was lower than those who did not answer: 34.8% vs 41.0%, respectively. Although these are not significant differences, we were not powered to detect a difference. A larger follow-up study is needed.
Sixth, our study population may not have been interested in ridesharing. Less than half of the patients stated that they were interested and less than half of those used rideshare to or from the clinic. Further qualitative work is needed to understand interests in transportation alternatives, such as rideshare, in making health care more accessible for low-income patients in urban settings. Similarly, targeting patients with specific transportation needs or preferences (eg, individuals who have clearly defined transportation barriers or patients more likely to be interested in ridesharing) may result in higher uptake and may be associated with missed appointment rates. Targeting specific patient populations, however, may increase the operational costs due to resources needed to identify and coordinate services for those patients. Each of these considerations represents a possible study or intervention limitation, affecting the interpretation of our findings. However, this study has several strengths. First, this was a large investigation of ridesharing that was simple and designed to be easily scaled or modified in areas where rideshare services are accessible. Second, our study was naturalized and pragmatic, with a control group unaware of the intervention and operationally meaningful outcomes measured through existing data sources. Third, although social determinants of health are widely recognized as a major contributor to premature deaths in the United States, 16 there is little evidence for effective or ineffective strategies that may guide health systems toward addressing these determinants. [17] [18] [19] In our study, we aimed to evaluate 1 intervention designed to address the barrier of transportation for 1 population. Similar studies of interventions for improving transportation as a means to better health care access are warranted and worth testing in other settings.
Conclusions
This study was undertaken to investigate rideshare medical transportation as a viable option for reducing missed appointments that could be easily integrated into the menu of transportation options available to low-income patients with Medicaid. A negative finding is important because it highlights that simply offering rideshare services to patients, which has been discussed within the health care industry, does not improve the attendance rate. It is possible that modifications to our model of providing rideshare-based transportation services or how we informed patients about the service might produce different results. Moreover, most studies of social interventions designed to improve health outcomes are often uncontrolled pre-post designs or cross-sectional studies, resulting in poor-quality evidence because of limitations inherent to these approaches. 20 Despite this trial's lack of success, controlled clinical trials examining the effect of interventions designed to address transportation needs and, more broadly, studying interventions that address the social determinants of health with the goal of improving health outcomes are needed and will have significant implications for future population health efforts.
Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. In phase 1, all patients sampled will receive the intervention arm (i.e. without a control) will be piloted to understand design challenges for Phase 2, such that we can create modifications to the design for optimal deployment in Phase 2. In order to understand these challenges, we will a) conduct a series of in-depth qualitative interviews of patients, b) conduct field notes by traveling with patients in a rideshare vehicle, and c) monitor uptake of the intervention. To better understand the transportation needs of patients in the West Philadelphia area who attend the Penn Medicine clinic (the same population exclusion and inclusion criteria as Phase 2), we will conduct in-depth qualitative interviews focused on previous transportation experiences and implementation themes related to acceptability and feasibility. For these interviews, patients will be asked after they had completed their clinic appointment and provided with a ride home as compensation for completing the qualitative interview. These qualitative interviews will take place in the return trip home from clinic, including time in the vehicle with the patient. Interviews will be audio-recorded. For the second component of Phase 1, the same researcher conducting the in-depth qualitative interviews will be recording observations with regards to challenges for the patient accessing a rideshare service or challenges on the return trip home. Anticipated challenges may include how patients and drivers manage mobility challenges, coordinating pickups in the absence of utilizing the commonly used rideshare smartphone app, or safety concerns by either the patient or driver. For the third component, we will record the uptake of the intervention (e.g., proportion of patients who are offered a ride who ultimately use it to get to and from clinic) based on variations in the design. For example, changing whether patients call a standard number to request a ride versus we call them, or the timing of the pre-pickup phone call to account for traffic patterns or rideshare care availability in order to standardize the timing of the phone call (e.g. 30 minutes before the pickup time vs. one hour before the pickup time) in order to make sure patients get to their predetermined destination on time (e.g., home or clinic). In phase 2 -the randomized control trial phase, telephone-based survey data will be collected from patients in the intervention arm where patients will be offered a rideshare service (RSS) transportation option to use on the day of their appointment. When offering the service to the intervention arm, we will consent the patient to participate in a pre-appointment and post-appointment survey at the same time. Patients will be compensated for completing the preappointment survey with a free RSS ride to and from their clinic. The pre-appointment survey contains questions regarding previous transportation modes and demographic questionnaire; and the postappointment survey will assess the patient's experience using RSS. For those who consent over the telephone days prior to their appointment, but do not ultimately use the RSS or do not show-up to their appointment, we will only have results from their pre-appointment survey as that is built into the telephone consent session.
Group Modifications
Describe necessary changes that will or have been made to the study instruments for different groups.
No group modification occurs in Phase 1, the only group modification occurs in phase 2, the randomized control trial phase. Here, both the intervention and control arms will receive a telephone reminder within one week of their appointment (the current standard of care) to control for the effect of a phone call that may remind the patient that they have an upcoming clinic appointment, potentially altering the decision of patients to attend their clinic appointment (our primary outcome of interest). In the control arm where patients do not receive an RSS offer, they will receive a standardized appointment reminder only. In the intervention arm, patients will receive a standardized appointment reminder and offered the RSS transportation option with the pre-appointment survey. Similarly, only the intervention arm will receive the post-appointment survey. When offering the service to the intervention arm, we will also consent the patient for both the pre-appointment and post-appointment survey. Patients will be compensated for completing the pre-appointment survey with a free RSS ride to and from their clinic. The pre-appointment survey contains questions regarding previous transportation modes and demographic questionnaire; and the post-appointment survey will assess the patient's experience using RSS. For those who consent but do not use the RSS or do not show-up to their appointment, we will only administer the pre-appointment survey as that is built into the telephone consent session.
Method for Assigning Subjects to Groups
Describe how subjects will be randomized to groups. During phase 2, the randomized control trial phase, patients on even number calendar days will be offered RSS while those on odd number days will not be offered. No group assignment will occur in phase 1.
Administration of Surveys and/or Process
Describe the approximate time and frequency for administering surveys and/or evaluations. For surveys, questionnaires and evaluations presented to groups and in settings such as high schools, focus group sessions or community treatment centers explain how the process will be administered and who will oversee the process. For instance, discuss the potential issues of having teachers and other school personnel administer instruments to minors who are students especially if the content is sensitive in nature. Describe the procedure for audio and videotaping individual interviews and/or focus groups and the storage of the tapes. For instance, if audio tape recording is to be used in a classroom setting, describe how this will be managed if individuals in the class are not participating in the study. Explain if the research involves the review of records (including public databases or registries) with identifiable private information. If so, describe the type of information gathered from the records and if identifiers will be collected and retained with the data after it is retrieved. Describe the kinds of identifiers to be obtained, (i.e. names, social security numbers) and how long the identifiers will be retained and justification for use. For phase 1, the pilot phase, in-person qualitative interviews will be audio-recorded after permission is granted from the patient using the informed consent process. This interview will occur over the course of the journey home for the patient. We will purposefully sample patients of varying age categories, genders, and geographic locations over the course of 2-6 week period. Additionally, questions regarding transportation challenges and demographic information will be asked, including age, race, and gender.
Patients will be made aware that we are also making notes regarding challenges observed while traveling with the patient. For phase 2, when offering the service to the intervention arm, we will consent the patient to participate in a pre-appointment (approximately 15 minutes including consent) and post-appointment survey (less than five minutes). Patients will be compensated for completing the pre-appointment survey with a free RSS ride to their clinic. The pre-appointment survey contains questions regarding previous transportation modes and demographic questionnaire; and the postappointment survey will assess the patient's experience using RSS. For those who consent preappointment but ultimately do not use the RSS or do not show-up to their appointment, we will only administer the pre-appointment survey because that occurs during the telephone consent.
Data Management
Describe how and who manages confidential data, including how and where it will be stored and analyzed. For instance, describe if paper or electronic report forms will be used, how corrections to the report form will be made, how data will be entered into any database, and the person(s) responsible for creating and maintaining the research database. Describe the use of pseudonyms, code numbers and how listing of such identifiers will be kept separate from the research data. Once qualitative interviews or surveys have been completed, each study participant will be assigned a unique identification number that will be linked to their name and survey data. These identification numbers will be added to each study participants's audiotapes (phase 1), field observation notes (phase 1), and electronically recorded survey data (phase 2) to allow for tracking of responses. Transcripts created from audiotapes in the phase 1 development phase will be stripped of any identifying information by transcribers educated in qualitative data preparation techniques and the importance of confidentiality. Transcripts will be stored in password protected sections of the computer. Phone surveys (phase 2) results will be entered into REDCap, a secure-web-based application that provides data management assistance for surveyed information. REDCap provides automated export procedures for seamless data downloads to excel and common statistical packages. Any paper study materials (including notes or data summaries) will be kept in locked cabinets. This information will be accessible only to study personnel who need the information for data collection. The PI(s) will be responsible for creating and maintaining the database. Following the completion of data collection and assessment of potential response bias, the file linking subject numbers and personal identifiers will be erased. This system will consist of two separate but related systems: a management information system (MIS) and primary data management system (PDMS). The MIS will track all subjects who were approached and will include their participation status, name, age, and zip code. Periodic reports will be generated to assess whether recruitment is proceeding on schedule and identify any recruitment problems. The PDMS will include all subject survey data. Relational database software, such as Microsoft Access, will be used to maximize management information tool flexibility and to prepare data files for statistical analysis. Any identifiable information will be destroyed no later than July 1, 2017 and most likely earlier than that date. Furthermore, the data will only be reported in an aggregated format, without individual identifiers. This includes avoiding the reporting of any identifiable information used in the analysis of these data.
Radiation Exposure* Are research subjects receiving any radiation exposure (e.g. X-rays, CT, Fluoroscopy, DEXA, pQCT, FDG, Tc-99m, etc.) that they would not receive if they were not enrolled in this protocol? No 
Status of contract
The following documents are currently attached to this item:
Grant Application (ldi2015pilotgrant_krisdachaiyachati.pdf)
Multi-Site Research
Other Sites
No other sites
Management of Information for Multi-Center Research Not applicable
There are no documents attached for this item.
Protocol
Abstract
We propose a randomized control trial (RCT) testing the impact of rideshare services (RSS) on reducing primary care clinic no-show rates for Medicaid patients, the main outcome of the study. We will assess the patient experience after each ride using a telephone-based survey. Secondary aims focus on characterizing transportation efficiencies (such as time between pickup and drop-off locations), measures of uptake, the timing of clinic attendance, and operational costs. The study has two phases. Phase 1 will focus on discovering the challenges of implementing the intervention through in-depth qualitative interviews, field observations occurring simultaneously as the interviews, and pilot testing different ways patients can access the RSS. For phase 2, the full pilot involving randomization for the intervention. All adults with established primary care at the Penn Medicine Clinics, who have Medicaid, do not require wheelchair accessible rides, and body mass index (BMI) less than 40 will be eligible.
Objectives
Overall objectives
We propose a randomized control trial (RCT) testing the impact of rideshare services (RSS) on outpatient no-show rates. In the intervention arm, we will administer pre-appointment and postappointment surveys to assess current transportation modes and the acceptability of using RSS. Secondary aims focus on describing the efficiency of the RSS transportation (e.g., travel distance and travel time), misuse of the service, clinic check-in times, and costs. Given the novelty, we will test the intervention in two phases. Phase 1 will focus on discovering the challenges of implementing the intervention through structured qualitative methods and field testing to inform the final operating procedures for phase 2, the randomized control trial.
Primary outcome variable(s)
Our primary outcome is for Phase 2 -the frequency of missed appointments in the intervention arm and the control arm.
Secondary outcome variable(s)
For the intervention arm only -patient perceptions of reliability, timeliness, and safety with regards to the RSS intervention. For both arms -clinic check in times.
Background
Reliable transportation for primary care appointments is a significant burden for low-income patients in urban areas, limiting their accessibility to outpatient, primary care and ultimately shifts their care utilization patterns towards more costly, acute care settings either because of preference or medical need. Surveys of low-income patients indicate that between 24-51% of patients reported having ever missed or rescheduled a clinic appointment because of unreliable transportation. Without reliable and accessible transportation, patients shift their preference away from primary care clinics towards the overuse of acute care settings for ambulatory care sensitive conditions -a key target of the U.S. Agency for Healthcare Research in Quality for reducing low-value, high cost care in our health system. A variety of transportation options exist for patients. However, traditional transportation modes are inconvenient, unreliable, or costly for low-income patients. Medicaid finances NEMT with door-to-door van services by outsourcing to private companies or will provide public transportation passes. The eligibility to access these services is broad for the Medicaid population in Pennsylvania, including individuals with supplemental security income benefits and pregnant women below the federal poverty level. However, NEMT services are seen as inconvenient, require advanced scheduling of 3-5 days, and are relatively inflexible to changes to the location or timing of pickups and drop-offs. Taxis are an alternative door-to-door service, but are costly. When personal vehicles are accessible, parking can be a significant time and financial burden. Finally, for low-income patients, the accessibility of friends and family are limited because they too have significant health care needs or require their personal vehicles for work. An RSS-based intervention that provides a cheap, reliable alternative transportation for lowincome patients to outpatient appointments may ultimately improve patient access to primary care services, potentially improving patient health and reduce costs in our healthcare system. In the long run, RSS could have a positive return on investment for a health system in a more capitated payment system or represent an alternative transportation strategy for state Medicaid programs.
Study Design
Phase* Not applicable
Design
We propose a mixed-methods study incorporating surveys into an RCT designed to improve patient transportation accessibility for Medicaid patients with primary c a r e a p p o i n t m e n t s a t t h e i n t e r n a l medicine practices at Penn Medicine. Our primary outcome is to determine the frequency of missed appointments in the intervention and control arm. This data will be complemented by pre-and postappointment surveys. The study population includes adult Medicaid patients with primary care appointments at Penn Medicine. The RSS in this study will be provided for free to patients, matching the current non-emergency medical benefit provided by the state Medicaid program and voucher based transportation. The study will be completed in two phases. Phase 1 will focus on discovering the challenges of implementing the intervention through field testing and qualitative interviews. In phase 1, all patients sampled will receive the intervention arm (i.e. without a control) will be piloted to understand design challenges for Phase 2, such that we can create modifications to the design for optimal deployment in Phase 2. In order to understand these challenges in Phase 1, we will a) conduct a series of in-depth qualitative interviews of patients, b) conduct field notes by traveling with patients in a ride-share vehicle, and c) monitor uptake of the intervention. Overall we will test the RSS design with approximately 75 patients until design challenges have been solved. Of the 75 patients we will randomly sample approximately 20 of them to complete in-depth interviews. The in-depth qualitative interviews will help us better understand the transportation needs of patients in the West Philadelphia area who attend the Penn Medicine clinic (the same population exclusion and inclusion criteria as Phase 2), allowing us to make any necessary adjustments to the design to match the transportation needs for low income patients. During the in-depth qualitative interviews, we will focus on previous transportation experiences and implementation themes related to acceptability and feasibility. For these interviews, patients will be asked after they had completed their clinic appointment and provided with a ride home as compensation for completing the qualitative interview. These qualitative interviews will take place in the return trip home from clinic, including time in the vehicle with the patient. Interviews will be audio-recorded. For the second component of Phase 1, the same researcher conducting the indepth qualitative interviews will be recording observations with regards to challenges for the patient accessing a rideshare service or challenges on the return trip home. Anticipated challenges may include how patients and drivers manage mobility challenges, coordinating pickups in the absence of utilizing the commonly used rideshare smartphone app, or safety concerns by either the patient or driver. For the third component, we will record the uptake of the intervention (e.g., proportion of patients who are offered a ride who ultimately use it to get to and from clinic) based on variations in the design. For the initial design, the patient will receive a phone call with one week which will serve as an appointment reminder, an offer to be a participant in this study, and instructions on how to access the RSS on the day of the appointment. Then on the morning of the appointment, the patient will receive a text reminder with instructions on how to access RSS. The patient calls a hotline to request the ride and a research team member coordinates the ride using a dispatch tool developed by Lyft. To test different designs, we may, for example, change whether patients call a standard number to request a ride versus we call them, or alter the timing of the pre-pickup phone call to account for traffic patterns or rideshare care availability in order to standardize the timing of the phone call (e.g. 30 minutes before the pickup time vs. one hour before the pickup time) in order to make sure patients get to their predetermined destination on time (e.g., home or clinic). This process will inform the final operating procedures for phase 2, the full trial of the intervention where we test the primary aim of missed appointments. Additional covariates will be collected from the electronic medical record, including Charleson comorbidity index, BMI, provider, missed appointment history, continuity, and basic demographic data. For both phases of the study, If patients have an address in W. Philadelphia but need a ride from a different location, they can still access RSS. They can only request a ride, though, that is no more than the cost of the ride from their home to the clinic (estimate $10). This is similar for the return ride home the cost of the ride cannot exceed the ride from the clinic to home. Therefore, patients will have the flexibility to take a ride from or to anywhere in the city within those cost limits. UPHS is currently a party to a non-disclosure agreement with Lyft. UPHS is also negotiating a services agreement for the purposes of the study and will consider future agreements with Lyft to provide transportation.
Study duration
Approximately 6-8 months. One to three months will be devoted towards the phase 1 field testing of the intervention. Phase 2 will be the RCT where we estimate it will take approximately three to five months to reach our target numbers in both arms.
Resources necessary for human research protection
Describe research staff and justify that the staff are adequate in number and qualifications to conduct the research. Describe how you will ensure that all staff assisting with the research are adequately informed about the protocol and their research related duties. Please allow adequate time for the researchers to conduct and complete the research. Please confirm that there are adequate facilities for the research. We have successfully completed numerous mixed-methods and RCT studies testing the implementation of novel methods for improved health care delivery and create innovative strategies in a variety of settings, including Penn Medicine. The team includes investigators experienced in primary care delivery, social determinants of health, survey methods, qualitative interview techniques, and rapid cycle innovation. The experience acquired and infrastructure developed from these studies will ensure successful completion of the proposed work and we have established infrastructure (physical and electronic) to ensure human subjects research protection. Moreover, we have teamed up with Lyft, who will be providing the technical support and web-based platform to access their drivers for this intervention. Lyft® is a nationwide, RSS company that utilizes a smartphone app and web-based interfaces for ride requests and financial transactions. We will hire a research assistant who will assist with contacting patients in both arms (per the protocol), coordinating the rides for patients, and collecting clinic level data. This research assistant will have have HIPAA certification and CITI training completed. UPHS is currently a party to a non-disclosure agreement with Lyft. UPHS is also negotiating a services agreement for the purposes of the study and will consider future agreements with Lyft to provide transportation.
Characteristics of the Study Population
Target population Adult (older than 18 years old), Medicaid patients with primary care appointments at the internal medicine practices at Penn Medicine. Patients included in the study will have established primary care at the Penn Medicine clinics and have addresses in the electronic medical record designating a West Philadelphia zip code. Patients with BMI greater than 40 or who require wheelchair accessible transportation will be excluded because of the limited availability of accommodating vehicles. These individuals will be screened through the electronic medical record for BMI before being called for consent and via the pre-appointment survey for patients requiring wheelchair accessible transportation. Over the phone, the latter group will be offered the ability to connect with Logisticare, the current company providing Medicaid sponsored wheelchair accessible rides to clinic. For phase 1, we will enroll up to 75 patients, of which 20 or so patients will receive in-depth qualitative interviews. For phase 2, we will enroll 572 patients in the intervention arm and compare them to 572 individuals in the control arm.
Subjects enrolled by Penn Researchers 667
Subjects enrolled by Collaborating Researchers 0
Accrual A weekly list of eligible patients and patient phone number(s) will be generated by the Penn Medicine clinic staff or by our research team based on a our pre-specified inclusion criteria. From this list we will be able to collect eligible patients for phase 1 and for phase 2 when we will require contact information for both the control and intervention arms. Any staff contacting patients will be HIPAA certified.
Key inclusion criteria
Adult (18 years old), Medicaid patients with primary care appointments at the internal medicine practices at Penn Medicine. Patients included in the study will have established primary care at the Penn Medicine clinics. Additionally, patients will have addresses in the West Philadelphia zip codes. 
Key exclusion criteria
Patients with BMI greater than 40 or who require wheelchair accessible transportation will be excluded because of inability to guarantee vehicles that will be able to accommodate patients' physical needs.
Vulnerable Populations
Populations vulnerable to undue influence or coercion None
Subject recruitment
Using the EPIC electronic medical record database, our research team will collaborate with the clinic staff to identify and call eligible patients within a week of their scheduled appointment to offer the RSS and obtain consent for the qualitative portions. If there is subject compensation, provide the schedule for compensation per study visit or session and total amount for entire participation, either as text or separate document
In phase 1 and phase 2, patients will receive a free RSS transportation for completing the qualitative interviews and questionnaires. Estimated $5-10 USD. The cost of the rides will not exceed the market rate of traveling from the western most part of West Philadelphia to the Penn Medicine Clinics. This study provides no more than minimal risk because patients all require some form of transportation to clinic, either walking or motor vehicle. For those not walking to clinic, we are simply providing a transportation alternative for the intervention arm. Currently, Medicaid patients are eligible to receive transportation services through Medicaid's Non-Emergency Medical Transport Program. For the control arm, their mode of transportation will be the typical mode they use to get to clinic.
Study Procedures
B.
The deception/incomplete disclosure should have no adverse effects on welfare. Please outline how all adverse effects are minimized.
Patients in the control arm will not be offered the rideshare service. They will not know they did not receive the intervention. Because our primary aim is missed appointment rates, we do not want to alter their motivation or mode they choose to use when attending their clinic by knowing they were not offered a ride or "lost" the opportunity to receive a free ride. This poses no more than minimal harm to the patients because they will not lose out on the opportunity to use the service and they travel to clinic as they normally would.
C. The IRB must determine that the value of the study is sufficient to warrant waiving some aspects of the requirement for full disclosure in the informed consent process. Please outline the scientific validity for using deception in this instance.
The deception is requested so as to not influence the behavior of patients in how they typically travel to clinic. Should patients know that this service is being tested and realize they are not receiving the intervention, they may engage differently with a future appointment, thereby altering our main outcome -missed appointments.
D. There is no alternative to address the scientific question in a valid manner but to use deception/ incomplete disclosure. Other effective, non-deceptive approaches are not feasible. Please detail why alternatives are not feasible.
By informing them of the rideshare program and that they are not offered the intervention may impact their impressions with the clinic (changing their behavior about whether they might attend the clinic) and therefore choose not to go to their clinic appointment. Alternatively, they might consider utilizing a rideshare service themselves. These choices and behavior changes would differentially impact our scientific question and make our results biased.
E. Debriefing is done, when appropriate, and the deception/incomplete disclosure is explained to the participant before the end of participation in the research. Please detail if you are debriefing participants, and if not, why not.
No. For the control arm, their interaction with the clinic is going to be how they typically engage and travel to their clinic. This study is not removing something from them nor is it interacting with them in any harmful way to impact their clinical care. The observation arm is simply receiving a clinical reminder. The only risk for the observers is that we are collecting data from their electronic medical record. We have protections in place for their privacy.
F. When appropriate, subjects could be informed prospectively of the use of deception/incomplete disclosure and consent to its use: see the suggested consent language: "In some research studies, the investigators cannot tell you exactly what the study is about before you participate in the study. We will describe the tasks in the study in a general way, but we can't explain the real purpose of the study until after you complete these tasks. When you are done, we will explain why we are doing this study, what we are looking at, and any other information you should know about this study. You will also be able to ask any questions you might have about the study's purpose and the tasks you did. Though we may not be able to explain the real purpose of the study until after you complete the tasks, there are no additional risks to those that have been described in this consent form."
Not applicable.
Analysis Plan
The most recent Stata version will be used for statistical analyses with all hypothesis testing conducted at a two-sided, type I error rate of 0.05. The primary analysis will consist of an unadjusted intent-totreat hypothesis testing using a logistic regression model to assess the binary of attending their clinic appointment versus not. We will estimate regression models adjusting for covariates of interests, including Charleson comorbidity index, BMI, provider, missed appointment history, continuity, and basic demographic data. Descriptive statistics will be used to analyze the survey results and secondary aims.
The following documents are currently attached to this item:
Are you conducting research outside of the United States? No
Data conÞdentiality
x Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study.
x Computer-based files will only be made available to personnel involved in the study through the use of access privileges and passwords.
Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
x Wherever feasible, identifiers will be removed from study-related information.
A Certificate of Confidentiality will be obtained, because the research could place the subject at risk of criminal or civil liability or cause damage to the subject's financial standing, employability, or liability.
x A waiver of documentation of consent is being requested, because the only link between the subject and the study would be the consent document and the primary risk is a breach of confidentiality. (This is not an option for FDA-regulated research.)
Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based surveys.
x Audio and/or video recordings will be transcribed and then destroyed to eliminate audible identification of subjects.
Subject Confidentiality
Protection against risk precautions are taken to ensure that strict confidentiality is maintained. All research materials will be inaccessible to anyone other than the investigators. Each subject will be assigned a unique identification number that will be linked to sensitive information, including the subject's name, mailing address, and phone number in a password protected data file stored on a secure server. These identification numbers will be added to each survey for tracking purposes. A separate file will be created, linking the patient and their identification numbers. Following the completion of our data analysis, the file linking patient numbers and personal identifiers will be erased. Any audio recordings used to create transcriptions will be eliminated and destroyed after analyzing the transcript.
No identifiable information will be transcribed. All survey data will use the study ID code and will not include any personally identifiable information. No results will be reported in a personally identifiable manner. Previous research we have conducted that has employed precautions has demonstrated that these techniques are very successful in assuring the protection of subjects. Personal identifiers (names, address, and telephone numbers) will be removed from the data set once calculations have been made. This pertains particularly to distance calculations between the home address or pickup/drop-off location and the clinic. These personal identifiers are used solely for the purposes of contacting the patients for the qualitative portions and to coordinate the transportation service.
Sensitive Research Information* Does this research involve collection of sensitive information about the subjects that should be excluded from the electronic medical record? No
Subject Privacy
Privacy refers to the person's desire to control access of others to themselves. Privacy concerns people, whereas confidentiality concerns data. Describe the strategies to protect privacy giving consideration to the following: The degree to which privacy can be expected in the proposed research and the safeguards that will be put into place to respect those boundaries. The methods used to identify and contact potential participants. The settings in which an individual will be interacting with an investigator. The privacy guidelines developed by relevant professions, professional associations and scholarly disciplines (e.g., psychiatry, genetic counseling, oral history, anthropology, psychology). The privacy of our subjects is a critical priority for our research team. Our main interaction with patients will occur in the initial pilot phase where we will observe and conduct interviews with patients en route to their clinic. For the main intervention, patients will receive a phone call. We will utilize their names and telephone numbers as a primary means of contacting them. For the intervention arm, interviews will occur over the telephone. Patients will always retain the option to not have their information or interviews used for the purposes of the qualitative portion of the study. Questionnaire data and observation notes will be deidentified and aggregated to protect the privacy of patients.
Data Disclosure
Will the data be disclosed to anyone who is not listed under Personnel? No. Only aggregate, de-identified data and analysis will be reported to non study personnel.
Data Protection* 
Genetic testing
If genetic testing is involved, describe the nature of the tests, including if the testing is predicative or exploratory in nature. If predictive, please describe plan for disclosing results to subjects and provision of genetic counseling. Describe how subject confidentiality will be protected Note: If no genetic testing is to be obtained, write: "Not applicable." Not applicable.
Consent
Consent Process
Overview
For Phase 1's in-depth qualitative interview consents will occur in person or over the phone. Study participants will receive a copy of a written consent form with a description of the study purpose and procedures, the risks and benefits of participation, the procedures for maintaining confidentiality, how to contact the study investigator with questions or to decline to participate, and that the decision about participation will have no effect on their medical care. Audio-recording of any interviews in phase 1 will only occur after consent has been completed. For those who are in Phase 1 but do not receive the in-depth qualitative interviews we will pilot the pre-and post-surveys that we are going to administer in Phase 2. This data will not be used in the final analysis as we may make modifications to the intervention or the questions in the surveys that will alter the response of participants. For Phase 2, patients will be asked to verbally consent to the study prior to administering the telephone-based preappointment and post-appointment surveys over the phone. They will retain the option to not complete the survey during the pre-and post-appointment phone call. We will be requesting approval from the IRB for consent without written documentation for the RCT portion of the study.
Children and Adolescents Not applicalbe
Adult Subjects Not Competent to Give Consent
Competency, in-person or over the phone, will be assessed by one of the research coordinators or research assistants. The assessment will be informal. No legally authorized representative will be used to provide consent.
Waiver of Consent
Waiver or Alteration of Informed Consent* Waiver of written documentation of informed consent: the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context 
Risk / Benefit
Potential Study Risks This study involves no more than minimal risks to subjects. Demographic data will be acquired from both the electronic medical record and surveys. Other covariates listed elsewhere will be extracted from the electronic medical record. A patient's choice to enter into a vehicle offered through a rideshare service will incur no greater risk, to our knowledge, then entering into the vehicle of a taxi or personal vehicle driven by the patient or acquaintance. These forms of transportation are already in use by patients. The additional domains of possible risk involves subject privacy and confidentiality. For the survey components of the study, the risk to privacy and confidentiality will be minimized because any identifying information (e.g., participant name, home address, and phone number) will be destroyed as soon as it is no longer necessary for the study. The study materials will be kept on a secure computer in the locked office of the PIs for the duration of the study. The data obtained by this study will only be reported in an aggregate format, never identifying any individual respondents and posing no risk of damage or liability to participants of the study.
Potential Study Benefits
The benefits of the study involve increased understanding of the impact of rideshare services on a patients ability to access their outpatient clinic appointment. Based on the outcomes of our study, we hope to inform medical centers about the impacts of addressing transportation barriers on the ability of patients to access medical appointments.
Alternatives to Participation (optional)
They can travel to clinic how they normally would.
Data and Safety Monitoring
The principle investigator and research personnel will meet every two weeks to discuss the study's progress, any breaches of privacy, data integrity concerns or safety concerns. An interim analysis will be conducted once we reach 100 and 300 patients in the intervention arm.
The following documents are currently attached to this item:
Risk / Benefit Assessment
The minimal risks to subject confidentiality and privacy will be greatly outweighed by the significant future benefits to improving the transportation access to outpatient clinics in order to understand the impact of improved transportation access on missed appointment rates for Medicaid patients.
General Attachments
The following documents are currently attached to this item: 
IRB Determination
If the change represents more than minimal risk to subjects, it must be reviewed and approved by the IRB at a convened meeting. For a modification to be considered more than minimal risk, the proposed change would increase the risk of discomfort or decrease benefit. The IRB must review and approve the proposed change at a convened meeting before the change can be implemented unless the change is necessary to eliminate an immediate hazard to the research participants. In the case of a change implemented to eliminate an immediate hazard to participants, the IRB will review the change to determine that it is consistent with ensuring the participant&prime;s continued welfare. 
Social and Biological Sciences
Study Instruments
Discuss the particulars of the research instruments, questionnaires and other evaluation instruments in detail. Provide validation documentation and or procedures to be used to validate instruments. For well know and generally accepted test instruments the detail here can be brief. More detail may be required for a novel or new instrument. For ethnographic studies identify any study instruments to be used (i.e. for deception studies) and describe in detail where, when and how the study will be conducted and who or what are the subjects of study. Note: For more information on how to conduct ethical and valid ethnographic research, follow the link For oral histories or interviews provide the general framework for questioning and means of data collection. If interviews or groups settings are to be audio taped or video taped describe in detail the conditions under which it will take place. Include a copy of any novel or new test instruments with the IRB submission. In phase 1 (the "Pilot"), all patients sampled will receive the intervention (i.e. without a control) to understand design challenges for Phase 2 (the "Trial"), such that we can create modifications to the design for optimal deployment in Phase 2. There is no difference in the study instruments used in Phase 1 or Phase 2. The only additional component for Phase 1 (the Pilot) will be monitoring the uptake of the intervention. Moreover, in Phase 1, there is no control arm, so all individuals called will be offered the service because we are testing variations in the design of administering the service. Regarding the study instruments, a telephone-based survey will be completed for those who are offered the rideshare service (RSS) transportation option to use on the day of their appointment (the pre-appointment survey) and within 24 hours of their appointment (the post-appointment survey). When offering the service to the intervention arm, we will consent the patient to participate in the pre-appointment and postappointment survey at the same time. Patients will be compensated for completing the pre-appointment survey with a free RSS ride to and from their clinic. The pre-appointment survey contains questions regarding previous transportation modes and demographic questions; and the post-appointment survey will assess the patient's experience using RSS. In addition, an in-depth interview will be audio-recorded directly after the post-appointment survey. These are meant to get open-ended feedback about the service and future modifications. We are audio-recording the in-depth questions only for accuracy. To monitor uptake in Phase 1, we will record the uptake of the intervention (e.g., proportion of patients who are offered a ride who ultimately use it to get to and from clinic) based on variations in the design. For example, changing whether patients call a standard number to request a ride versus we call them, or the timing of the pre-pickup phone call to account for traffic patterns or rideshare care availability in order to standardize the timing of the phone call (e.g. 30 minutes before the pickup time vs. one hour before the pickup time) in order to make sure patients get to their predetermined destination on time (e.g., home or clinic). For those who consent over the telephone days prior to their appointment, but do not ultimately use the RSS or do not show-up to their appointment, we will only have results from their pre-appointment survey as that is built into the telephone consent session.
Group Modifications
Method for Assigning Subjects to Groups
Administration of Surveys and/or Process
Describe the approximate time and frequency for administering surveys and/or evaluations. For surveys, questionnaires and evaluations presented to groups and in settings such as high schools, focus group sessions or community treatment centers explain how the process will be administered and who will oversee the process. For instance, discuss the potential issues of having teachers and other school personnel administer instruments to minors who are students especially if the content is sensitive in nature. Describe the procedure for audio and videotaping individual interviews and/or focus groups and the storage of the tapes. For instance, if audio tape recording is to be used in a classroom setting, describe how this will be managed if individuals in the class are not participating in the study. Explain if the research involves the review of records (including public databases or registries) with identifiable private information. If so, describe the type of information gathered from the records and if identifiers will be collected and retained with the data after it is retrieved. Describe the kinds of identifiers to be obtained, (i.e. names, social security numbers) and how long the identifiers will be retained and justification for use. There is no difference in the study instruments used in Phase 1 or Phase 2 or how they are administered. Regarding the study instruments, a telephone-based survey will be completed for those who are offered the rideshare service (RSS) transportation option to use on the day of their appointment (the preappointment survey) and within 24 hours of their appointment (the post-appointment survey). When offering the service to the intervention arm, we will consent the patient to participate in the preappointment and post-appointment survey at the same time. Patients will be compensated for completing the pre-appointment survey with a free RSS ride to and from their clinic. The preappointment survey contains questions regarding previous transportation modes and demographic questions; and the post-appointment survey will assess the patient's experience using RSS. In addition, an in-depth interview will be audio-recorded directly after the post-appointment survey. These are meant to get open-ended feedback about the service and future modifications. We are audio-recording the in-depth questions only for accuracy.
Data Management
Describe how and who manages confidential data, including how and where it will be stored and analyzed. For instance, describe if paper or electronic report forms will be used, how corrections to the report form will be made, how data will be entered into any database, and the person(s) responsible for creating and maintaining the research database. Describe the use of pseudonyms, code numbers and how listing of such identifiers will be kept separate from the research data. Once qualitative interviews or surveys have been completed, each study participant will be assigned a unique identification number that will be linked to their name and survey data. These identification numbers will be added to each study participants's audio recording and electronically recorded survey data for tracking of responses. Transcripts created from audiotapes of the in-depth interviews will be stripped of any identifying information by transcribers educated in qualitative data preparation techniques and the importance of confidentiality. Transcripts will be stored in password protected sections of the computer. Survey responses will be entered into a database behind the Penn Medicine Academic Computing Services Firewall. Any paper study materials (including notes or data summaries) will be kept in locked cabinets. This information will be accessible only to study personnel who need the information for data collection. The PI(s) will be responsible for creating and maintaining the database. Following the completion of data collection and assessment of potential response bias, the file linking subject numbers and personal identifiers will be erased. This system will consist of two separate but related systems: a management information system (MIS) and primary data management system (PDMS). The MIS will track all subjects who were approached and will include their participation status, name, age, and zip code. Periodic reports will be generated to assess whether recruitment is proceeding on schedule and identify any recruitment problems. The PDMS will include all subject survey data. Relational database software, such as Microsoft Access, will be used to maximize management information tool flexibility and to prepare data files for statistical analysis. Any identifiable information will be destroyed no later than July 1, 2017 and most likely earlier than that date. Furthermore, the data will only be reported in an aggregated format, without individual identifiers. This includes avoiding the reporting of any identifiable information used in the analysis of these data.
Radiation Exposure* Are research subjects receiving any radiation exposure (e.g. X-rays, CT, Fluoroscopy, DEXA, pQCT, FDG, Tc-99m, etc.) that they would not receive if they were not enrolled in this 
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Protocol
Abstract
We propose a randomized control trial (RCT) testing the impact of rideshare services (RSS) on reducing primary care clinic no-show rates for Medicaid patients, the main outcome of the study. We will assess the patient experience after each ride using a telephone-based survey. Secondary aims focus on characterizing transportation efficiencies (such as time between pickup and drop-off locations), measures of uptake, the timing of clinic attendance, and operational costs. The study has two phases. Phase 1 (the "Pilot") will focus on discovering the challenges of implementing the intervention by pilot testing different ways patients can access the RSS. For phase 2 (the "Trial"), the study will involve randomization of patients for the intervention. All adults with established primary care at the Penn Medicine Clinics, who have Medicaid, and do not require wheelchair accessible rides will be eligible.
Objectives
Overall objectives
We propose a randomized control trial (RCT) testing the impact of rideshare services (RSS) on outpatient no-show rates. In the intervention arm, we will administer pre-appointment and postappointment surveys to assess current transportation modes and the acceptability of using RSS. Secondary aims focus on describing the efficiency of the RSS transportation (e.g., travel distance and travel time), misuse of the service, clinic check-in times, and costs. Given the novelty, we will test the intervention in two phases. Phase 1 will focus on discovering the challenges of implementing the intervention to inform the final operating procedures for phase 2, the randomized control trial.
Primary outcome variable(s)
Secondary outcome variable(s)
Background
Study Design
Design
We propose a mixed-methods study incorporating surveys into an RCT designed to improve patient transportation accessibility for Medicaid patients with primary c a r e a p p o i n t m e n t s a t t h e i n t e r n a l medicine practices at Penn Medicine. Our primary outcome is to determine the frequency of missed appointments in the intervention and control arm. This data will be complemented by pre-and postappointment surveys. The study population includes adult Medicaid patients with primary care appointments at Penn Medicine. The RSS in this study will be provided for free to patients, matching the current non-emergency medical benefit provided by the state Medicaid program and voucher based transportation. The study will be completed in two phases. Phase 1 (the "Pilot") will focus on discovering the challenges of implementing the intervention through field testing. In phase 1, all patients sampled will receive the intervention (i.e. without a control) will be piloted to understand design challenges for Phase 2, such that we can create modifications to the design for optimal deployment in Phase 2. In order to understand these challenges in Phase 1, we will a) conduct survey and in-depth interviews over the telephone and b) monitor uptake of the intervention. Overall we will test the RSS design with approximately 75 patients until design challenges have been solved. Of the 75 patients we will randomly sample approximately 20 of them to complete in-depth interviews. The indepth qualitative interviews will help us better understand the transportation needs of patients in the West Philadelphia area who attend the Penn Medicine clinic (the same population exclusion and inclusion criteria as Phase 2), allowing us to make any necessary adjustments to the design to match the transportation needs for low income patients. During the in-depth qualitative interviews, we will focus on previous transportation experiences and implementation themes related to acceptability and feasibility. For these interviews, patients will be asked after they had completed their clinic appointment and provided with a ride home as compensation for completing the qualitative interview. These qualitative interviews will take place over the phone. Interviews will be audio-recorded. For the third component, we will record the uptake of the intervention (e.g., proportion of patients who are offered a ride who ultimately use it to get to and from clinic) based on variations in the design. For the initial design, the patient will receive a phone call with one week which will serve as an appointment reminder, an offer to be a participant in this study, and instructions on how to access the RSS on the day of the appointment. Then on the morning of the appointment, the patient will receive a text reminder with instructions about the driver and time of pickup. The patient can also call a hotline to request the ride and a research team member coordinates the ride using a dispatch tool developed by Lyft. To test different designs, we may, for example, change whether patients call a standard number to request a ride versus we call them, or alter the timing of the pre-pickup phone call to account for traffic patterns or rideshare care availability in order to standardize the timing of the phone call (e.g. 30 minutes before the pickup time vs. one hour before the pickup time) in order to make sure patients get to their predetermined destination on time (e.g., home or clinic). This process will inform the final operating procedures for phase 2, the full trial of the intervention where we test the primary aim of missed appointments. Additional covariates will be collected from the electronic medical record, including Charleson comorbidity index, provider, missed appointment history, continuity, and basic demographic data. For both phases of the study, If patients have an address in W. Philadelphia but need a ride from a different location, they can still access RSS. They can only request a ride, though, that is no more than the cost of the ride from their home to the clinic (estimate $10). This is similar for the return ride home the cost of the ride cannot exceed the ride from the clinic to home. Therefore, patients will have the flexibility to take a ride from or to anywhere in the city within those cost limits. UPHS has completed a non-disclosure agreement, Business Associate, and Service Agreement with Lyft.
Study duration
Resources necessary for human research protection
Describe research staff and justify that the staff are adequate in number and qualifications to conduct the research. Describe how you will ensure that all staff assisting with the research are adequately informed about the protocol and their research related duties. Please allow adequate time for the researchers to conduct and complete the research. Please confirm that there are adequate facilities for the research. We have successfully completed numerous mixed-methods and RCT studies testing the implementation of novel methods for improved health care delivery and create innovative strategies in a variety of settings, including Penn Medicine. The team includes investigators experienced in primary care delivery, social determinants of health, survey methods, qualitative interview techniques, and rapid cycle innovation. The experience acquired and infrastructure developed from these studies will ensure successful completion of the proposed work and we have established infrastructure (physical and electronic) to ensure human subjects research protection. Moreover, we have teamed up with Lyft, who will be providing the technical support and web-based platform to access their drivers for this intervention. Lyft® is a nationwide, RSS company that utilizes a smartphone app and web-based interfaces for ride requests and financial transactions. We will hire a research assistant who will assist with contacting patients in both arms (per the protocol), coordinating the rides for patients, and collecting clinic level data. This research assistant will have have HIPAA certification and CITI training completed. UPHS has completed a non-disclosure agreement, Business Associate, and Service Agreement with Lyft.
Characteristics of the Study Population
Target population Adult (older than 18 years old), Medicaid patients with primary care appointments at the internal medicine practices at Penn Medicine. Patients included in the study will have established primary care at the Penn Medicine clinics and have addresses in the electronic medical record designating a West Philadelphia zip code. Patients who require wheelchair accessible transportation will be excluded because of the limited availability of accommodating vehicles. These individuals will be screened through the electronic medical record for BMI before being called for consent and via the preappointment survey for patients requiring wheelchair accessible transportation. Over the phone, the latter group will be offered the ability to connect with Logisticare, the current company providing Medicaid sponsored wheelchair accessible rides to clinic. For phase 1, we will enroll up to 75 patients, of which 20 or so patients will receive in-depth qualitative interviews. For phase 2, we will enroll 572 patients in the intervention arm and compare them to 572 individuals in the control arm.
Subjects enrolled by Penn Researchers 667
Subjects enrolled by Collaborating Researchers 0
Key inclusion criteria
Adult (18 years old), Medicaid patients with primary care appointments at the internal medicine practices at Penn Medicine. Patients included in the study will have established primary care at the Penn Medicine clinics. Additionally, patients will have addresses in the West Philadelphia zip codes.
Key exclusion criteria
Patients who require wheelchair accessible transportation will be excluded because of inability to guarantee vehicles that will be able to accommodate patients' physical needs. 
Vulnerable Populations
Populations vulnerable to undue influence or coercion None
Subject recruitment
In phase 1 and phase 2, patients will receive a free RSS transportation for completing the qualitative interviews and questionnaires. Estimated $5-10 USD. The cost of the rides will not exceed the market rate of traveling from the western most part of West Philadelphia to the Penn Medicine Clinics.
Study Procedures
Suicidal Ideation and Behavior Does this research qualify as a clinical investigation that will utilize a test article (ie-drug or biological) which may carry a potential for central nervous system (CNS) effect(s)? No
Procedures
Not applicable
Deception
Does your project use deception? Ye s
A. Deception/incomplete disclosure is typically only acceptable in studies with no more than minimal risk. Please detail why this study is minimal risk.
This study provides no more than minimal risk because patients all require some form of transportation to clinic, either walking or motor vehicle. For those not walking to clinic, we are simply providing a transportation alternative for the intervention arm. Currently, Medicaid patients are eligible to receive transportation services through Medicaid's Non-Emergency Medical Transport Program. For the control arm, their mode of transportation will be the typical mode they use to get to clinic.
B.
E. Debriefing is done, when appropriate, and the deception/incomplete disclosure is explained to the participant before the end of participation in the research. Please detail if you are debriefing participants, and if not, why not.
Not applicable
Analysis Plan
The most recent Stata version will be used for statistical analyses with all hypothesis testing conducted at a two-sided, type I error rate of 0.05. The primary analysis will consist of an unadjusted intent-totreat hypothesis testing using a logistic regression model to assess the binary of attending their clinic appointment versus not. We will estimate regression models adjusting for covariates of interests, including Charleson comorbidity index, provider, missed appointment history, continuity, and basic demographic data. Descriptive statistics will be used to analyze the survey results and secondary aims.
The following documents are currently attached to this item:
Are you conducting research outside of the United States? No
Data conÞdentiality
Subject Confidentiality
Protection against risk precautions are taken to ensure that strict confidentiality is maintained. All research materials will be inaccessible to anyone other than the investigators. Each subject will be assigned a unique identification number that will be linked to sensitive information, including the subject's name, mailing address, and phone number in a password protected data file stored on a secure server. These identification numbers will be added to each survey for tracking purposes. A separate file will be created, linking the patient and their identification numbers. Phone surveys results will be entered into REDCap, a secure-web-based application that provides data management assistance for surveyed information. REDCap provides automated export procedures for seamless data downloads to excel and common statistical packages. Following the completion of our data analysis, the file linking patient numbers and personal identifiers will be erased. Any audio recordings used to create transcriptions will be eliminated and destroyed after analyzing t h e t r a n s c r i p t . N o i d e n t i fi a b l e information will be transcribed. All survey data will use the study ID code and will not include any personally identifiable information. No results will be reported in a personally identifiable manner. Previous research we have conducted that has employed precautions has demonstrated that these techniques are very successful in assuring the protection of subjects. Personal identifiers (names, address, and telephone numbers) will be removed from the data set once calculations have been made. This pertains particularly to distance calculations between the home address or pickup/drop-off location and the clinic. These personal identifiers are used solely for the purposes of contacting the patients for the qualitative portions and to coordinate the transportation service.
Subject Privacy
Data Disclosure
Data Protection*
x Name
x Street address, city, county, precinct, zip code, and equivalent geocodes 
eAppendix. Methods
Pilot period
Prior to starting the clinical trial, we conducted a planned, 2 week pilot study to address possible implementation challenges related to the intervention. There were no technical concerns related to the Lyft dispatch tool. We refined procedures for data storage, allocation of research tasks among research assistants, and determined the maximum number of calls the research staff could successfully make each day for the intervention or control arm:
approximately 15 per day.
Quality assurance checks
Quality checks were completed on patient data that were extracted from the electronic medical record's servers to verify its accuracy by cross validating it with patient and appointment data seen by clinical staff ("practice rosters"). To ensure that the electronically generated list from the server identified all patients who met study criteria (not ride eligibility criteria), we cross referenced a 1 week period of patients appearing on the practice rosters for eligible patients and calculated the proportion captured. Of the 93 patients who were identified as eligible from the practice rosters, the electronically generated list from the data server identified 89 of these patients (95.7%) and, more importantly, did not include patients who did not meet study eligibility criteria. 
